PNC-27: A Targeted Peptide Therapy for Leukemia and Solid Tumors
Exploring the selective anticancer properties of PNC-27, a novel peptide targeting cancer cell membranes.
Get a Quote & SampleProduct Core Value
PNC-27 Peptide
PNC-27 is a synthetic peptide that exhibits remarkable selectivity in targeting and eliminating cancer cells while sparing healthy ones. Its mechanism involves binding to the HDM-2 protein, which is predominantly expressed on the surface of cancer cells. This specific interaction triggers the formation of transmembrane pores, leading to the rapid necrosis of tumor cells. Unlike many conventional chemotherapies, the efficacy of PNC-27 is independent of the p53 status of the cancer cells and does not induce apoptosis.
- Discover the unique mechanism of action of PNC-27 in targeting cancer cells via HDM-2 binding.
- Learn how PNC-27 induces tumor cell necrosis, a distinct pathway from apoptosis, offering a novel therapeutic approach.
- Understand the p53-independent activity of PNC-27, making it effective even in cancers with p53 mutations.
- Explore the application of synthetic peptide for cancer therapy, particularly in the context of leukemia treatment.
Key Advantages
Selective Cancer Cell Targeting
PNC-27 demonstrates precise targeting of cancer cells by interacting with membrane-bound HDM-2, a key factor in its efficacy for leukemia treatment.
Minimal Off-Target Effects
Unlike many treatments, PNC-27 shows minimal toxicity to normal cells, making it a potentially safer option for patients undergoing cancer therapy.
Versatile Application
The peptide's effectiveness against various solid tumors and its role in leukemia treatment highlight its broad potential in oncology research and application.
Key Applications
Leukemia Treatment
Research indicates the PNC-27 mechanism of action is effective against various leukemia cell lines, suggesting its potential in treating hematological malignancies.
Solid Tumor Therapy
PNC-27 has demonstrated significant efficacy in preclinical studies against a range of solid tumors, highlighting its broad anticancer capabilities.
Oncology Research
As a novel synthetic peptide, PNC-27 serves as a valuable tool in understanding cancer cell biology and developing new therapeutic strategies.
Targeted Drug Development
The peptide's specific binding to HDM-2 makes it an excellent candidate for targeted drug development in the fight against cancer.